Sirolimus binds to a family of intracellular binding proteins termed FKBPs (FK binding proteins) and such complexes act as a specific inhibitor of m-TOR (Figure 1), whose pathway is involved in cell growth and metabolism, and it is deregulated in many cancer types, including osteosarcoma [67,68,69]. This evidence concerns the gene MTOR and cancer.